Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 in Healthy Subjects Following a Subcutaneous Administration of a Lyophilized Formulation or a Solution Formulation

Trial Profile

Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 in Healthy Subjects Following a Subcutaneous Administration of a Lyophilized Formulation or a Solution Formulation

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Cluster headache; Migraine
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 04 Dec 2017 Planned End Date changed from 31 Mar 2018 to 1 Jan 2018.
    • 11 Jun 2017 Results of part A and part B, presented at the 59th Annual Scientific Meeting of the American Headache Society.
    • 08 Mar 2017 Planned End Date changed from 1 Aug 2016 to 31 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top